Author Archives: admin


Stem Cell Clinic > Articles by: admin

Former SeaChange actor Tom Long has died, five months after being cleared of cancer, & more in News in 5. – Mamamia

By Stem Cell Treatment

Its absolutely incredible to think back to when we first started, McGrath said.

CA and the SCG Trust came to us and offered us the SCG Test in remembrance of Jane and to support the foundation and my family.

What it has grown into now is absolutely incredible.

If what weve done here has an impact in other places for other charities then its absolutely brilliant.

The McGrath Foundation aimed to raise $1.6 million from the Sydney Test between Australia and New Zealand, to take their tally of nurses from 135 to 147.

They were still in pursuit of reaching their goal by late on day three, with takings at the ground up on last year.

This years Test has been played in the backdrop of the bushfire emergency that engulfs the nation.

It was notable on Sunday that as the smoke began to be seen at the SCG, the pink boundary signs were one of the few things to shine through the lingering Sydney haze.

For the McGrath Foundation that hits close to home too.

Three-quarters of their nurses are in rural and regional areas while McGraths own childhood home of Narromine is among the most drought-affected in NSW.

I heard a story of lady whose family is impacted by the fires, foundation ambassador Tracy Bevan said.

She left her family, rode a bike, got on a boat and she went on the boat for chemotherapy.

She knew she had to go and have that treatment because of the impact of that insidious disease.

Wildlife official Mike Williams has been appointed to lead the recovery on Kangaroo Island from the devastating bushfires.

The National Parks and Wildlife Service senior executive has been named the local recovery coordinator to support islanders as they come to grips with their needs over the coming weeks and months.

This is an unprecedented tragedy for the Kangaroo Island community, who are now facing a recovery effort on a scale never seen before on the island, SA Human Services Minister Michelle Lensink said.

Mr Williams will work with locals to coordinate recovery measures and help residents, primary producers, tourism operators and other local businesses navigate a way forward.

His appointment recognises the unique challenges facing Kangaroo Island as it embarks on the process of recovery, including geographic isolation, losses relative to population, impacts on local economic activity and community wellbeing.

There are fears as many as half of South Australias Kangaroo Islands koala population has been wiped out. Report in 7NEWS at 6pm. #KIfires #7NEWS https://t.co/DgeaVRKBpw

7NEWS Sydney (@7NewsSydney) January 5, 2020

Read more:
Former SeaChange actor Tom Long has died, five months after being cleared of cancer, & more in News in 5. - Mamamia

Father-of-three raises cash for last chance MS treatment – Wakefield Express

By Stem Cell Treatment

A father-of-three has launched a fundraiser for medical treatment that he hopes will help tackle his debilitating illness.

Phil Swindin, from Darrington, was diagnosed with Multiple Sclerosis in 2004, and has suffered major problems with his health ever since.

His symptoms have now escalated, leaving him unable to walk more than a metre without support, and relying on caffeinated drinks for short bursts of energy.

He hopes to travel to a private facility in Mexico for a new type of treatment known as Autologous Haematopoietic Stem Cell Transplantation (AHSCT), which has been linked with improvements in MS.

Phil said: Living with MS is constant and terrifying, as you just get more and more disabled and whatever you do very little can be done.

My MS symptoms have fluctuated and reared its ugly head at the most inappropriate times and limited my normal physical or mental ability.

Its caused major hidden problems in mobility, mental health, energy levels and so many other symptoms.

I long to do simple things like doing things with my kids, playing football or going for a walk but its out of the question.

All other avenues have failed so Im left with only one option, to fundraise for private treatment.

Phil and his wife Alison launched the fundraiser last month, and have already raised more than 28,000.

The couple also hope to organise a ball in the Spring to help boost funding,

Alison said: People have just been wonderful. People who we havent spoken to for years have been in touch and their words of support are fantastic.

It sort of feels much more achievable than when we started it. Were just trying to keep it moving, with more things happening all the time.

Phils treatment is currently booked for April, but will have to be postponed if the funds are not raised before then.

Phil has also been supported by Ackworth mum-of-two Kate Dawson, who successfully underwent the treatment in 2017 and described the results as life-changing.

Visit gofundme.com/f/transplant4phil to find out more.

Read more from the original source:
Father-of-three raises cash for last chance MS treatment - Wakefield Express

Cardio Round-up: Look Back at 2019, The Importance of Sleep, and More – DocWire News

By Stem Cell Treatment

This weeks Cardio Round-up features a look back at what you may have missed during the holidays, as well as some of the big 2019 cardiology stories.

The past year saw some big stories like the Apple Heart study, presented at ACC.19, which essentially validated the ability of a wearable device (an Apple iWatch) equipped with a tachogram-tracking algorithm was able to detect pulse irregularities associated with atrial fibrillation. Icosapent ethyl also featured prominently, gaining an FDA approval for the reduction of cardiovascular disease risk as an add-on to statin therapy in high-risk patients with hypertriglyceridemia. Dapagliflozin (highlighted in the DAPA-HF study) also was shown to be an effective treatment for heart failure in both diabetic and non-diabetic patients.

2019 In Cardiology: Apple Heart Study Lands; Icosapent Ethyl Gets FDA Nod for New Indication; Dapagliflozin For Nondiabetics; and More

A new observational study published inEuropacesuggests it is possible to monitor and predict individual progression ofatrial fibrillation (AFib) using pacemakers or defibrillators.We aimed to study the progression of AER in individual patients with implantable devices and AFib episodes, the paper authors wrote. The study results indicated that the slope of AAR changes during the progression of AFib showed patient-specific patterns correlating with the time-to-completion of AER (R2 = 0.85). This technology opens up enormous possibilities in personalized medicine for AFib patients because it allows us to determine the progression rate of the arrhythmia in each individual and to optimize the timing of medical intervention with current treatment options, one of the researchers said in a press release.

Personalized Medicine for AFib: How Electric Activity in the Heart Can Predict Individual Progression of Atrial Fibrillation

A research team, publishing the study in the Journal of Molecular and Cellular Cardiology, worked on converting adipogenic mesenchymal stem cells, which reside within fat cells, into cardiac progenitor cells. The ensuing cardiac progenitor cells can be programmed to aid heartbeats as a sinoatrial node (SAN), which is part of the electrical cardiac conduction system.We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current, said study co-author Bradley McConnell, associate professor of pharmacology, in a press release. Results of this study show that the SHT5 combination of transcription factors can reprogram CPCs into Pacemaker-like cells.

The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment

Diabetes mellitus is an independent predictor for heart failure, according to the findings of a study published inMayo Clinic Proceedings. In this study, using the Rochester Epidemiology Project, researchers assessed the long-term impact ofdiabeteson the development of heart failure by including 116 study subjects with diabetes, who were matched 1:2 based on age, hypertension, sex, coronary artery disease and diastolic with 232 participants without diabetes. The results showed that that diabetes is an independent risk factor for the development of heart failure. Over the duration of 10 years, 21% of participants with diabetes developed heart failure, independent of other causes. The researchers observed that by comparison, only 12% of patients without diabetes developed heart failure. The key takeaway is that diabetes mellitus alone is an independent risk factor for the development of heart failure, wrote one of the authors.

Diabetes is an Independent Predictor for Heart Failure

A new study suggests that regularly getting a good nights sleep isnt just a helpful overall health recommendation but is also an essential way to keep risk for heart disease and stroke down. The paper, published in theEuropean Journal of Cardiology, included more than 300,000 participants initially free of cardiovascular disease (CVD) from UK Biobank. According to the results, there were 7,280 documented cases of incident CVD (4,667 coronary heart disease and 2,650 stroke) cases. Participants with a sleep score of 5 had a 35% reduced risk for CVD, a 34% reduced risk for coronary heart disease, and a 34% reduced risk for stroke when compared to participants with a score of 0-1.As with other findings from observational studies, our results indicate an association, not a causal relation, one of the authors said in a press release. However, these findings may motivate other investigations and, at least, suggest that it is essential to consider overall sleep behaviors when considering a persons risk of heart disease or stroke.

Getting Quality Sleep, and the Right Amount, Can Offset Genetic Susceptibility for Heart Disease and Stroke Risk

View post:
Cardio Round-up: Look Back at 2019, The Importance of Sleep, and More - DocWire News

Novel discovery in gene therapy to treat kidney diseases – WeForNews

By Gene Therapy Clinics

Jaipur, Jan 4 : The sorry state of Kotas J.K. Lon Hospital is reflected in a government-appointed panels report which shows that around 105 children died in a span of over a month due to cold shivering in the hospital as it lacked everything a normal hospital should have.

The committee formed by the Rajasthan government to probe the lacunae in the hospital resulting in the deaths of kids has confirmed in its report that infants died due to hypothermia, a medical emergency that occurs when the body temperature falls below 95 F (35 C). The normal body temperature is 98.6 F (37 C).

Even as the kids in the hospital continued to die in the biting winter cold, the hospital did not have enough stocks of lifesaving equipment, said the report.

The newborns should have body temperature of 36.5 degree celcius; therefore they were kept on warmers where their temperature stays normal. However, as the hospital lacked functional warmers, their body temperature continued to plummet.

The report said that 22 nebulisers out of 28 were dysfunctional, 81 infusion pumps out of 111 were not working and the same was the story with para monitors and pulse oxymeters.

What made the matters worse was the absence of oxygen pipeline in the hospital due to which oxygen was supplied to kids with the help of cylinders.

Surprisingly, the ICU was not fumigated for months, the report said.

The children continued to die in December as Chief Minister Ashok Gehlot celebrated the launch of Nirogi Rajasthan campaign in the state, said former health minister Rajendra Rathore.

Hospital officials said most paediatricians of JK Lon Hospital have been posted at Kotas New Medical College. The nursing employees, already under-staffed, prefer to stay idle while ward boys rule the roost in the J.K. Lon Hospital, said an official.

Also, the hospital staff continued with the whitewash in wards where infants suffering from pneumonia were admitted for oxygen.

According to sources, there was no record of 40 heaters purchased for kids. A hospital official said despite Rs 6-crore funds lying with the hospital, no purchase has been made.

On Friday, when state Health Minister Raghu Sharma visited the hospital, a green carpet welcome was given to him, a gesture hardly suited for the grim situation prevailing in the hospital. After drawing severe criticisms, the carpet was rolled back.

A five-month-old girl suffering from pneumonia died the same day when Sharma visited the hospital as the officials were busy getting the walls cleaned.

Former Health Minister Rajendra Rathore said rampant transfer of specialists on political grounds has deprived the patients of availing the best medical services.

Rathore said that during BJPs rule, we ensured that all specialists were kept at one place irrespective of any political leaning.

He said the present government has not had annual repair contracts of the equipment purchased under its tenure. There is no medical inspection arrangement for the equipment purchased, Rathore said.

Gehlot in December celebrated one year of the formation of his government and launched the Nirogi Rajasthan campaign. He also announced Janata Clinics and spoke about introducing Right to Health.

How can Right to Health be launched when there is no homework done by the state government? questioned Rathore.

The Nirogi campaign is only on papers as there has been no discussion on it with panchayats or other stakeholders, Rathore said. In a situation when 11,000 posts of doctors are lying vacant, how can the government talk about Janata clinics? he asked.

State Health Minister Raghu Sharma when contacted by IANS was not available for comment.

(Archana Sharma can be contacted at [emailprotected])

The rest is here:
Novel discovery in gene therapy to treat kidney diseases - WeForNews

Duke researchers land $6M in federal grants to advance gene editing – WRAL Tech Wire

By Somatic Stem Cells

DURHAM Hemophilia. Cystic fibrosis. Duchenne muscular dystrophy. Huntingtons disease. These are just a few of the thousands of disorders caused by mutations in the bodys DNA. Treating the root causes of these debilitating diseases has become possible only recently, thanks to the development of genome editing tools such as CRISPR, which can change DNA sequences in cells and tissues to correct fundamental errors at the source but significant hurdles must be overcome before genome-editing treatments are ready for use in humans.

Enter the National Institutes of Health Common FundsSomatic Cell Genome Editing (SCGE)program, established in 2018 to help researchers develop and assess accurate, safe and effective genome editing therapies for use in the cells and tissues of the body (aka somatic cells) that are affected by each of these diseases.

Todaywith three ongoing grants totaling more than $6 million in research fundingDuke University is tied with Yale University, UC Berkeley and UC Davis for the most projects supported by the NIH SCGE Program.

In the 2019 SCGE awards cycle, Charles Gersbach, the Rooney Family Associate Professor of Biomedical Engineering, and collaborators across Duke and North Carolina State University received two grants: the first will allow them to study how CRISPR genome editing affects engineered human muscle tissues, while the second project will develop new CRISPR tools to turn genes on and off rather than permanently alter the targeted DNA sequence. This work builds on a 2018 SCGE grant, led by Aravind Asokan, professor and director of gene therapy in the Department of Surgery, which focuses on using adeno-associated viruses to deliver gene editing tools to neuromuscular tissue.

Duke engineers improve CRISPR genome editing with biomedical tails

There is an amazing team of engineers, scientists and clinicians at Duke and the broader Research Triangle coalescing around the challenges of studying and manipulating the human genome to treat diseasefrom delivery to modeling to building new tools, said Gersbach, who with his colleagues recently launched the Duke Center for Advanced Genomic Technologies (CAGT), a collaboration of the Pratt School of Engineering, Trinity College of Arts and Sciences, and School of Medicine. Were very excited to be at the center of those efforts and greatly appreciate the support of the NIH SCGE Program to realize this vision.

For their first grant, Gersbach will collaborate with fellow Duke biomedical engineering faculty Nenad Bursac and George Truskey to monitor how genome editing affects engineered human muscle tissue. Through their new project, the team will use human pluripotent stem cells to make human muscle tissues in the lab, specifically skeletal and cardiac muscle, which are often affected by genetic diseases. These systems will then serve as a more accurate model for monitoring the health of human tissues, on-target and off-target genome modifications, tissue regeneration, and possible immune responses during CRISPR-mediated genome editing.

Duke researchers: Single CRISPR treatment provides long-term benefits in mice

Currently, most genetic testing occurs using animal models, but those dont always accurately replicate the human response to therapy, says Truskey, the Goodson Professor of Biomedical Engineering.

Bursac adds, We have a long history of engineering human cardiac and skeletal muscle tissues with the right cell types and physiology to model the response to gene editing systems like CRISPR. With these platforms, we hope to help predict how muscle will respond in a human trial.

Gersbach will work with Tim Reddy, a Duke associate professor of biostatistics and bioinformatics, and Rodolphe Barrangou, the Todd R. Klaenhammer Distinguished Professor in Probiotics Research at North Carolina State University, on the second grant. According to Gersbach, this has the potential to extend the impact of genome editing technologies to a greater diversity of diseases, as many common diseases, such as neurodegenerative and autoimmune conditions, result from too much or too little of certain genes rather than a single genetic mutation. This work builds on previous collaborations between Gersbach, Barrangou and Reddy developing bothnew CRISPR systems for gene regulationandto regulate the epigenome rather than permanently delete DNA sequences.

Aravind Asokan leads Dukes initial SCGE grant, which explores the the evolution of next generation of adeno-associated viruses (AAVs), which have emerged as a safe and effective system to deliver gene therapies to targeted cells, especially those involved in neuromuscular diseases like spinal muscular atrophy, Duchenne muscular dystrophy and other myopathies. However, delivery of genome editing tools to the stem cells of neuromuscular tissue is particularly challenging. This collaboration between Asokan and Gersbach builds on their previous work in usingAAV and CRISPR to treat animal models of DMD.

We aim to correct mutations not just in the mature muscle cells, but also in the muscle stem cells that regenerate skeletal muscle tissue, explainsAsokan. This approach is critical to ensuring long-term stability of genome editing in muscle and ultimately we hope to establish a paradigm where our cross-cutting viral evolution approach can enable efficient editing in multiple organ systems.

Click through to learn more about theDuke Center for Advanced Genomic Technologies.

(C) Duke University

Original post:
Duke researchers land $6M in federal grants to advance gene editing - WRAL Tech Wire

TEDCO funds open again for applications – Maryland Daily Record

By Stell Cell Research

Four Maryland Technology Development Corporation funds will begin accepting applications for investments again after they had delayed investments while adapting regulations to an oversight law passed by the Maryland General Assembly last year.

The Builder Fund, the Maryland Venture Fund, the Rural Business Innovation Initiative and the Seed Fund are now accepting applications for investment.

Stephen Auvil (File photo)

We are thrilled to bring these application portals live after the team has worked hard to finalize the regulations, Stephen Auvil, TEDCOs executive vice president, said in a statement. Its our goal to get back to what TEDCO does best, and thats building great, Maryland-based startups and continuing to grow innovation and entrepreneurship in the state.

A legislative audit issued last February found issues that included how TEDCO directed funding to companies that were not primarily based in Maryland and invested in companies that had associations with the Maryland Venture Funds advisory committee.

In the aftermath of the audit, lawmakers put more restrictions in place to govern how TEDCO invests its money and what oversights are in place to govern the agency.

One of the lawmakers requirements was that TEDCO develop an application process for its investment programs. That application process is now ready, TEDCO said Friday.

The Builder Fund is designed to help startups founded by people from economically disadvantaged background. The Rural Business Innovation Initiative invests in companies from rural Maryland. The Maryland Venture Fund is a venture capital fund focused on growth stage companies, and the Seed Fund invests in seed-stage companies.

TEDCO explained to lawmakers last month how it had crafted its regulations to comply with the oversight law.

The new regulations more clearly define what a Maryland business is and how it can qualify for investments. They also define how a company not defined as a Maryland business can receive investment if it will have a substantial economic impact on the state.

Under the new regulations, state businesses must have their principal base of operations in Maryland; have more than half of their workforce in Maryland; and intend to maintain their base of operations in Maryland.

TEDCO also has created provisions that would allow it to claw back its investment if a company leaves the state.

While TEDCO is accepting applications now, investments could still take a little while to happen. The agencys Maryland Venture Fund Authority does not yet have a quorum of members appointed to disburse funds.

The Maryland Venture Fund will also only be accepting applications from current Maryland Venture Fund portfolio companies. It anticipates accepting applications from other companies for the fund later this spring.

TEDCO operates eight funds. Programs like the Maryland Innovation Initiative, which helps commercialize university technology, and the Maryland Stem Cell Research Fund were not affected by the new regulations.

See the rest here:
TEDCO funds open again for applications - Maryland Daily Record

Cell Culture Protein Surface Coating Market Competitive Environment and Higher Growth Rate with Forecast to 2025 – Filmi Baba

By Stell Cell Research

Global Cell Culture Protein Surface Coating Market: Snapshot

The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions. These cells are used to develop model systems for study and research of cellular structures as well as for drug discovery and genetic engineering.

To know Untapped Opportunities in the MarketCLICK HERE NOW

Thus, the growing scope of cell cultures in various applications has led to the development of the 3D cell culture technique, which has been considered one of the key factors responsible for the overall past development of the cell culture protein surface coatings market. Earlier, only a meager percentage of researchers preferred using 3D cell culture technique for drug discovery. However, there has been a dynamic shift from the traditional methods to the current cell culture methods.

Moreover, commercial production of drugs and biologics such as proteins, antibodies, and vaccines using cell culture has helped expand the scope of the latter in the global market. Commercial production has provided extensive business opportunities to manufacturers in the global market. Diverse applications of stem cells such as development of bone grafts and artificial tissue are also expected to fuel the demand for cell culture protein surface coatings over the forecast period. In addition, increasing cell culture applications in toxicology studies and cell-based assays are further pushing the growth of the market.

Get Discount on Latest Report @CLICK HERE NOW

Global Cell Culture Protein Surface Coating Market: Overview

Cell culture protein surface coatings help in improving cell attachment, growth, and differentiation. They facilitate consistent performance in various cell-based assays and in-vitro culture by improving cell adhesion. A variety of adhesion proteins and other biological materials derived from various sources are being used to enhance performance in cell culture, especially in cell lines that are hard to attach, such as transfected cells. The major types of cell culture are animal-derived protein, human-derived protein, synthetic protein, and plant-derived protein. Good cell attachment has gained increased significance in recent years for improving the recovery of cells from frozen cultures and increasing the stability of attached surfaces. With constant advances in stem cell therapies, a number of advanced protein surface coatings have emerged to study stem cells and to further the potential of regenerative medicine. These developments have positively affected the growth of the global cell culture protein surface coating market.

Global Cell Culture Protein Surface Coating Market: Key Trends

The increasing focus of numerous biotechnology companies and research laboratories on stem cell research to develop therapies for a range of chronic diseases is a key factor propelling the cell culture protein market. Considerable investment by the governments of various countries to fund several R&D activities related to regenerative medicine has fuelled the market. Coupled with this, the rising demand for biopharmaceutical products such as antibodies, vaccines, and drugs has stimulated the demand for cell culture protein surface coatings. The growing research on stem cells for finding therapies for various cardiovascular and neurological diseases is expected to boost the market in the coming years. The growing prominence of 3D cell culture over 2D cell cultures is expected to unlock exciting opportunities in the cell culture protein surface coating market.

Global Cell Culture Protein Surface Coating Market: Market Potential

The American Heart Association (AHA), together with the Paul G. Allen Frontiers Group, announced in April, 2017 two grantseach worth US$1.5 millionto scientists working on cardiovascular extracellular matrix (ECM) research. Interested researchers have to apply for grants by May 10, and each of the two winners will be entitled to the magnanimous sum.

The ECM regulates all vital cell functions and is considered a highly useful biomaterial for investigators. This can be applied as a stable coating to be used in a variety of cell cultures. The initiative focused on investigating the role of ECM in the initiation and progression of a number of cardiovascular diseases, such as hypertensive heart disease, ischemic heart disease, cardiomyopathies, congenital cardiovascular malformations, and atherosclerosis and vascular diseases. The funding will further the investigation into the diagnosis, prevention, and treatment of cardiovascular diseases. One of the most commonly used protein surface coatings used in ECM is collagen, which facilitates cell adherence, growth, migration, differentiation, and proliferation. The major research initiatives, opine the AHA, will be greatly useful in setting up a new paradigm in research in cell structure in biosciences.

Global Cell Culture Protein Surface Coating Market: Regional Outlook

North America is a prominent market for cell culture protein surface coatings and is expected to exhibit significant growth over the forecast period. The impressive growth in the regional market is attributed to the presence of a robust healthcare infrastructure and considerable advances in stem cell research. In addition, the soaring demand for regenerative medicines for a range of autoimmune therapies is expected to fuel the demand for surface coatings for improving the performance of in-vivo culture.

The Asia Pacific market for cell culture protein surface coating is poised to offer lucrative avenues for players in the market. Favorable regulations for biologics development and a burgeoning biotechnology industry are the factors expected to lead to substantial demand for cell culture protein surface coatings.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Cell Culture Protein Surface Coating Market: Competitive Analysis

The market is fairly competitive due to the presence of a large number of regional and global vendors. Leading vendors are actively focused on providing solutions having cell attachment ability and promoting in-vitro cell functions for a variety of cell types to gain competitive edge over others. Leading players operating in this market include Sigma-Aldrich Corporation, Agilent Technologies, Thermo Fisher Scientific, EMD Millipore, Corning Incorporated, Biomedtech Laboratories Inc., Neuvitro Corporation, and Progen Biotechnik GmbH.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Visit link:
Cell Culture Protein Surface Coating Market Competitive Environment and Higher Growth Rate with Forecast to 2025 - Filmi Baba

Human Embryonic Stem Cells | The Embryo Project Encyclopedia

By Embryonic Stem Cells

Human Embryonic Stem Cells

Stem cells are undifferentiated cells that are capable of dividing for long periods of time and can give rise to specialized cells under particular conditions. Embryonic stem cells are a particular type of stem cell derived from embryos. According to US National Institutes of Health (NIH), in humans, the term embryo applies to a fertilized egg from the beginning of division up to the end of the eighth week of gestation, when the embryo becomes a fetus. Between fertilization and the eighth week of gestation, the embryo undergoes multiple cell divisions. At the eight-cell stage, roughly the third day of division, all eight cells are considered totipotent, which means the cell has the capability of becoming a fully developed human being. By day four, cells begin to separate and form a spherical layer which eventually becomes the placenta and tissue that support the development of the future fetus. A mass of about thirty cells, called the inner cell mass, forms at one end of the sphere and eventually becomes the body. When the sphere and inner cell mass are fully formed, around day 5, the pre-implantation embryo is referred to as a blastocyst. At this point the cells in the inner cell mass have not yet differentiated, but have the ability to develop into any specialized cell type that makes up the body. This property is known as pluripotency. As of 2009, embryonic stem cells refer to pluripotent cells that are generally derived from the inner cell mass of blastocysts.

In November 1998, two independent publications announced the first successful isolation and culture of pluripotent human stem cells. While working at the Wisconsin National Primate Research Center, located at the University of Wisconsin-Madison, James A. Thomson and his team of researchers cultured human embryonic stem cells from the inner cell mass of donated embryos originally produced for in vitro fertilization. The characteristics of the cultured cells were consistent with previously identified features in animal stem cells. They were capable of long-term self-renewal and thus could remain undifferentiated for long periods of time; they had particular surface markers; and they were able to maintain a normal and stable karyotype. Thomsons team also observed derivatives of all the three germ layersendoderm, mesoderm, and ectoderm. Since the three germ layers precede differentiation into all the cell types in the body, this observation suggested that the cultured cells were pluripotent. The team published Embryonic Stem Cell Lines Derived from Human Blastocysts, in the 6 November Science issue. Soon afterwards, a research team led by John D. Gearhart at the Johns Hopkins School of Medicine, published Derivation of Pluripotent Stem Cells from Cultured Human Primordial Germ Cells in Proceedings of the National Academy of Science. The paper detailed the process by which pluripotent stem cells were derived from gonadal ridges and mesenteries extracted from aborted five-to-nine week old human embryos. Gearhart and his team noted the same observations as Thomsons team. Despite coming from different sources, according to NIH, the resultant cells seem to be the same.

The largest source of blastocysts for stem cell research comes from in vitro fertilization (IVF) clinics. Used for reproductive purposes, IVF usually produces an abundance of viable blastocysts. Excess blastocysts are sometimes donated for research purposes after obtaining informed consent from donors. Another potential method for producing embryonic stem cells is somatic cell nuclear transfer (SCNT). This has been successfully done using animal cells. The nucleus of a differentiated adult cell, such as a skin cell, is removed and fused with an enucleated egg, an egg with the nucleus removed. The egg, now containing the genetic material from the skin cell, is believed to be totipotent and eventually develops into a blastocyst. As of mid-2006, attempts to produce human embryonic stem cells using SCNT have been unsuccessful. Nonetheless, scientists continue to pursue this method because of the medical and scientific implications of embryonic stem cells lines with an identical genetic makeup to particular patients. One problem faced in tissue transplants is immune rejection, where the host body attacks the introduced tissue. SCNT would be a way to overcome the incompatibility problem by using the patients own somatic cells.

Recent discoveries in cultivating human embryonic stem cells may potentially lead to major advancements in understanding human embryogenesis and medical treatments. Previously, limitations in access and environmental control have stunted research initiatives aimed at mapping out the developmental process. Insights into differentiation factors may lead to treatments into such areas as birth defects. Manipulation of the differentiation process may then lead to large supplies of stem cells for cell-based therapies on patients with Parkinsons disease, for example. In theory adult stem cells can also be cultivated for such purposes, but isolating and identifying adult stem cells has been difficult and the prospects for treatment are more limited than using embryonic stem cells.

Despite the potential benefits that may come about through human embryonic stem cell research, not everyone in the public embraces it. Several ethical debates surround this newly developing research field. Much of the debate stems from differing opinions on how we should view embryos: is an embryo a person? Should an embryo be considered property? Ethical concerns in embryonic stem cell research include destroying human blastocysts, laws surrounding informed consent, and particularly for SCNT, misapplication of techniques for reproductive cloning. For the latter concern, SCNT does produce a blastocyst which contains stem cell clones of an adult cell, but the desired application is in growing replacement tissues. Still, a portion of the public fears the hypothetical one day, when someone decides to use SCNT to develop and raise a human clone.

The public debate continues, advancing along with the changes in the field. As of 2006, public opinion polls showed that majority of religious and non-religious Americans now support embryonic stem cell research, but opinions remain divided over whether it is legitimate to create or use human blastocysts solely for research.

Wu, Ke, "Human Embryonic Stem Cells".

(2010-09-13). ISSN: 1940-5030 http://embryo.asu.edu/handle/10776/2055.

Arizona State University. School of Life Sciences. Center for Biology and Society. Embryo Project Encyclopedia.

Arizona Board of Regents Licensed as Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported (CC BY-NC-SA 3.0) http://creativecommons.org/licenses/by-nc-sa/3.0/

See the article here:
Human Embryonic Stem Cells | The Embryo Project Encyclopedia

Embryonic stem cell | biology | Britannica

By Embryonic Stem Cells

Embryonic stem cell | biology | Britannica rn rn rntrn rn"}

biology

THIS IS A DIRECTORY PAGE. Britannica does not currently have an article on this topic.

Alternative Titles:ES cell, ESC

Embryonic stem cells (often referred to as ES cells) are stem cells that are derived from the inner cell mass of a mammalian embryo at a very early stage of development, when it is composed of a hollow sphere of dividing cells

In contrast, embryonic stem cells (ESCs) can be harvested once and cultured indefinitely. Moreover, ESCs are pluripotent, meaning that they can be directed to differentiate into any cell type, which makes them an ideal cell source for regenerative medicine.

condemned medical research using embryonic stem cells, though it endorsed research with adult stem cells. While many theologians, clergy, and laypersons agreed with church policy on these matters, many others disagreed and even chose to defy it.

which point a culture of embryonic stem cells (ESCs) can be created from the inner cell mass of the blastocyst. Mouse, monkey, and human ESCs have been made using SCNT; human ESCs have potential applications in both medicine and research.

Evans and a colleague discovered embryonic stem cells (often referred to as ES cells) in mice. These stem cells are derived from the inner cell mass of a mammalian embryo at a very early stage of development. After determining that ES cells could serve as vehicles for the transmission of

in the late 1980s with embryonic stem cells. Wilmut and his colleagues were interested primarily in nuclear transfer, a technique first conceived in 1928 by German embryologist Hans Spemann. Nuclear transfer involves the introduction of the nucleus from a cell into an enucleated egg cell (an egg cell that has

Your preference has been recorded

Here is the original post:
Embryonic stem cell | biology | Britannica

Embryonic Stem Cell | California’s Stem Cell Agency

By Embryonic Stem Cells

Diabetes mellitus currently afflicts approximately 370 million people worldwide, with projections of over 550 million by the year 2030 (sources: World Health Organization; International Diabetes Federation). In the year 2000 there were approximately 2 million cases of diabetes in California (source: Diabetes Control Program, California Department of Health Services). Further, the disease disproportionately affects certain minority groups and the elderly. Despite the use of insulin and advances in its delivery, the human cost of diabetes is underscored by the financial costs to society: tens of billions of dollars each year in California alone. The primary cause of type 1 diabetes, and contributing significantly to type 2 diabetes as well, is the loss of insulin-producing pancreatic beta cells. The CIRM Diabetes Disease Team Project is developing an innovative beta cell replacement therapy for insulin-requiring diabetes. If successful, the therapy will go beyond insulin function, and will perform the full array of normal beta cell functions, including responding in a more physiological manner than manual or mechanized insulin self-administration. Because they will be more physiological, the replacement cells could reduce the long-term effects of diabetes. Moreover, the cell therapy will alleviate patients of the constant monitoring of blood glucose, painful insulin injections, and the ever-present risk of overdosing with insulin. For these reasons, it is possible that the product could transform the diabetes treatment landscape dramatically and even replace pharmaceutical insulin in the market. This product will be available in California first, through clinical testing, and if approved by the FDA for commercial production, will eventually help hundreds of thousands of Californians with diabetes. The product will substantially increase quality of life for patients and their families, while significantly reducing the health care burden in the state. The proposed project will employ Californian doctors and scientists, and success will prove highly noteworthy for the state. Lastly, once commercially marketed, the product will yield additional jobs in manufacturing, sales, and related industries, and generate revenue for California. Given the market need and the clear feasibility, the product could become the most significant stem cell-based medical treatment of the coming decade, and that will be a tremendous achievement for California, its taxpayers, and CIRM.

Link:
Embryonic Stem Cell | California's Stem Cell Agency

→←